Study finds weight loss results drive continued Ozempic use despite nausea and other side effects, based on real world ...

According to recent data, patients initiating semaglutide had a substantially greater risk of developing NAION versus those starting SGLT2 inhibitors. Although rare, semaglutide initiation can lead to ...

The study found that the perceived effectiveness of Ozempic for weight loss is the primary driver of patient satisfaction and intent to continue treatment, even when experiencing side effects.

By Tarun Sai Lomte Widely used weight-loss and diabetes drugs show clear benefits, but emerging evidence clarifies their side effects, rare risks, and what clinicians should monitor long term. Review: ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...

Demand for GLP-1 drugs continues to climb, boosted by a major price drop and the FDA’s approval of an oral Wegovy pill that ...

GLP-1 receptor agonists, originally developed for type 2 diabetes, are now witnessing soaring demand for weight management, with drugs like Ozempic gaining widespread popularity, particularly on ...

An AI-designed obesity drug targeting the GIP receptor shows over 31% weight loss in preclinical tests, raising hopes for next-generation metabolic treatments beyond GLP-1 drugs.

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Losing weight is no longer just about discipline and diet. GLP-1 drugs are becoming the "fast track" path to weight loss, redefining body and beauty standards for women. | Mind and Body, Lifestyle, ...

Drake Bell joins NY living, where he is using his voice to share his story like never before and releasing his new single ...

GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think about obesity, diabetes and weight loss. Headlines often describe them as ...